METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM

HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.
Keep Reading
If you are building a startup in Hong Kong, your first source of support may be closer than you think.
Updated
May 7, 2026 1:16 PM

Main Building of the University of Hong Kong. PHOTO: ADOBE STOCK
Across Hong Kong’s public universities, entrepreneurship is now part of the campus ecosystem. Many universities offer startup funding, mentorship, training, workspace, investor access and pathways into larger incubation programmes such as Hong Kong Science and Technology Park (HKSTP) and Cyberport.
For student founders, researchers and alumni, this can be a useful place to begin. You may be able to test an idea, build a prototype, form a company or apply for early funding through your own university before looking for external investors.
The challenge is knowing where to start. Each university has its own startup programmes, eligibility rules and funding structure. Some are designed for student ideas. Others are built for research commercialization, deep tech ventures or startups already preparing to raise investment. Below is a practical guide to startup support and university startup funding at five major publicly funded universities in Hong Kong.

HKU offers a wide range of entrepreneurship support through HKU Techno-Entrepreneurship Core, also known as HKU TEC. Its programmes cover early ideas, deep tech projects, Greater Bay Area (GBA) expansion, research commercialization and investor matching.
HKU is especially relevant for founders working with university research, intellectual property or technology-led business ideas. It also has entry-level support for students and graduates who are still testing an idea.
Best fit: HKU works well for student founders, researchers and alumni who want a structured route from idea stage to technology commercialization.

CityUHK’s main startup platform is HK Tech 300. It is one of the clearest university startup pathways in Hong Kong because it is built in stages: training, seed funding, angel investment and access to external funding.
The programme is open to CityUHK students, alumni, research staff and members of the public using CityUHK intellectual property or technology.
Best fit: CityUHK is a strong choice for founders who want a step-by-step startup journey with clear funding stages.

HKUST has a broad startup ecosystem with support for students, alumni, researchers and faculty. Its entrepreneurship pathway covers idea exploration, prototyping, MVP testing, research commercialization and investment.
The university’s startup support is especially strong for technology companies, deep tech projects and teams commercialising HKUST research.
Best fit: HKUST is especially useful for tech startups, deep tech teams and founders who need a route from prototype to commercialization.

PolyU’s startup support is practical and product-focused. Its programmes cover early ideas, seed-stage teams, Greater Bay Area expansion, translational research and investment.
This makes PolyU a good fit for founders working on engineering, hardware, applied technology, social impact or commercialization of university research.
Best fit: PolyU is well suited for product-led startups, applied technology projects, GBA expansion and founders who want industry-facing support.

CUHK offers support for student founders, researchers and alumni through the Pi Centre and the Knowledge Transfer Office. Its ecosystem covers pre-incubation, TSSSU funding, early translational research, social impact projects and Greater Bay Area entrepreneurship.
CUHK is especially useful for students who want to start with an idea and later move into funding, mentorship or external incubation.
Best fit: CUHK is a good starting point for student founders who need pre-incubation support, and for researchers moving early-stage ideas toward commercial use.
There is no single best programme for every founder. The right choice depends on your stage, your university connection and the type of startup you are building.
Hong Kong’s university startup ecosystem is bigger than many founders realize. If you are a student, alumnus, researcher or university-linked founder, your campus may already offer a route into funding, mentorship, workspace and incubation.
The key is to choose a programme that matches your current stage. Some founders should start with idea validation. Others may be ready for seed funding, TSSSU support or investment.
Before applying, check the latest deadline and eligibility rules on the official university page. These programmes change often, and some funding rounds open only once or twice a year.